Circular RNAs (circRNAs) and the Next Generation of RNA Therapeutics: Unparalleled Stability, Sustained Protein Production, and New Horizons in Disease Treatment

Abstract
The unprecedented success of linear messenger RNA (mRNA) vaccines during the COVID-19 pandemic has firmly established RNA therapeutics as a revolutionary pillar of modern biotechnology. However, linear mRNA molecules suffer from inherent structural limitations: they are highly susceptible to rapid degradation by cellular exonucleases, require sophisticated and costly lipid nanoparticle (LNP) formulations, necessitate strict cold-chain storage, and typically yield transient protein expression. These limitations have driven the scientific community to explore more robust RNA architectures. Circular RNAs (circRNAs), a class of naturally occurring, covalently closed-loop RNA molecules lacking 5' caps and 3' poly-A tails, have emerged as a groundbreaking alternative. Their unique continuous structure renders them highly resistant to exonuclease-mediated degradation, resulting in a vastly extended intracellular half-life and sustained protein translation. This comprehensive review article, with an analytical and highly practical approach, examines the molecular mechanisms of circRNA biogenesis (back-splicing), their engineered production strategies (such as permuted introns and ribozymes), and advanced purification methods (like HPLC and RNase R treatment) essential for therapeutic-grade manufacturing. Furthermore, the article explores the transformative applications of circRNAs in vaccine development (offering longer-lasting immunity), in vivo CAR-T cell engineering, protein replacement therapies for metabolic disorders, and the expression of therapeutic peptides. It critically discusses the immunological profile of circRNAs, particularly their reduced activation of innate immune sensors like RIG-I and Toll-like receptors, while also addressing the translational challenges, including low translation initiation efficiency, structural complexity, and large-scale manufacturing hurdles, outlining the future landscape of this extraordinary RNA modality in precision medicine.

Keywords: Circular RNAs, RNA Therapeutics, Protein Replacement, In Vitro Transcription, Lipid Nanoparticles, Biotechnology.

1. Introduction
The therapeutic landscape has been fundamentally transformed by the realization that RNA is not merely a messenger but a programmable drug. Linear mRNA therapeutics, while highly effective, operate like a fleeting software update; they instruct the cell to produce a protein for a short period before the RNA is degraded. This transience is advantageous in scenarios where temporary protein expression is desired (e.g., expressing CRISPR nucleases for gene editing), but it is a major drawback for applications requiring long-term protein supplementation or durable immune responses.

The discovery that RNA can exist in a covalently closed, circular format dates back to the 1970s, but until recently, circRNAs were considered mere splicing errors or curiosities. The advent of high-throughput RNA sequencing revealed that circRNAs are abundant, stable, and highly conserved across eukaryotic organisms, possessing crucial endogenous regulatory functions, particularly acting as microRNA sponges. This realization sparked a biotechnological revolution: if nature uses circular structures for stability, why not engineer them as next-generation therapeutics? This article provides an exhaustive review of circRNA technology, bridging the gap between molecular biology and translational medicine.

2. Theoretical Framework and Literature Review
2.1. Structural Uniqueness and Mechanism of Stability
The defining feature of a circRNA is its continuous, closed-loop structure, formed by a process called "back-splicing," where a downstream splice donor site is joined to an upstream splice acceptor site. This covalent linkage lacks the free ends (5' and 3' termini) that are the primary targets for cellular exonucleases. As a result, circRNAs can persist in cells for days, compared to the hours-long half-life of linear mRNA. This prolonged presence translates to higher cumulative protein yield and allows for significantly lower dosing in clinical applications. Furthermore, their unique folding structures make them more thermally stable, potentially simplifying cold-chain logistics.

2.2. Engineering and Manufacturing of Therapeutic circRNAs
To manufacture circRNAs therapeutically, scientists utilize in vitro transcription (IVT) followed by a circularization step. Two primary strategies are employed:

· Permuted Introns and Exons (PIE): The DNA template is designed such that the gene of interest is flanked by permuted intronic sequences. During transcription, these introns fold into a specific secondary structure (a "kissing loop") that facilitates the spliceosome-independent circularization of the RNA.
· Ribozyme-Mediated Ligation: RNA sequences (ribozymes) with catalytic activity are incorporated at the ends. The ribozymes cleave themselves and ligate the remaining ends together to form a circle.
Crucially, ensuring the purity of the circRNA product is a monumental challenge. The manufacturing process generates a mix of linear precursor RNAs, which must be removed using rigorous techniques like High-Performance Liquid Chromatography (HPLC) and treatment with RNase R (an exonuclease that digests linear RNA but leaves circRNAs intact). Any residual linear RNA can trigger potent, unwanted immune responses.

2.3. Translation Initiation in circRNAs
Because circRNAs lack a 5' cap structure—which is essential for the standard cap-dependent translation mechanism of linear mRNAs—they must rely on alternative translation initiation pathways. The most common strategy engineered by scientists is the insertion of an Internal Ribosome Entry Site (IRES) upstream of the coding sequence. The IRES forms a complex RNA structure that directly recruits the ribosome to the RNA, bypassing the need for a 5' cap. Additionally, researchers are exploring the use of N6-methyladenosine (m6A) modifications within the circRNA to act as a "cap-independent translation enhancer," a mechanism naturally utilized by the cell.

3. Practical and Industrial Applications
3.1. Next-Generation Vaccines
While linear mRNA vaccines were a triumph, circRNA vaccines offer the promise of prolonged antigen expression. This can lead to more robust and durable immune responses, potentially reducing the need for booster shots. Preclinical studies have shown that circRNA vaccines against various pathogens can induce higher neutralizing antibody titers and stronger T-cell responses that persist for much longer periods than their linear counterparts.

3.2. In Vivo CAR-T Cell Engineering
In previous articles, we discussed the complexities of ex vivo CAR-T therapy (extracting, modifying, and reinfusing a patient's T-cells). circRNAs offer a path to in vivo CAR-T therapy. By encapsulating circRNAs encoding the CAR (Chimeric Antigen Receptor) in targeted LNPs, researchers can inject the drug directly into a patient. The LNPs specifically target T-cells in the bloodstream, delivering the circRNA, which then instructs the T-cells to become cancer-killing CAR-T cells. Because circRNA is stable, it can maintain the CAR expression long enough for the T-cells to eliminate the tumor, without the need for complex and expensive cell harvesting.

3.3. Protein Replacement Therapy
For genetic disorders characterized by missing or defective proteins (e.g., ornithine transcarbamylase deficiency causing urea cycle disorders, or hemophilia), circRNA offers a viable protein replacement strategy. By delivering circRNA encoding the missing protein, the patient's liver or muscles can continuously produce the protein. The superior stability of circRNA reduces the frequency of administration, improving patient compliance and quality of life.

3.4. Industrial and Clinical Challenges

· Translation Efficiency: The internal ribosome entry site (IRES) used to initiate translation in circRNAs is often less efficient than the natural 5' cap of linear mRNA. Optimizing IRES sequences or engineering synthetic translation initiation elements is a major focus of current biotech research.
· Manufacturing Complexity: Circularization is often inefficient, and separating the circular product from linear precursors at an industrial scale is costly. Scaling up the HPLC purification process while maintaining GMP (Good Manufacturing Practice) standards presents significant engineering hurdles.
· Innate Immunogenicity: While circRNAs are less immunogenic than linear unmodified mRNAs, they can still be recognized by certain innate immune sensors (such as RIG-I or PKR). Encapsulation in LNPs and chemical modification of the nucleotides (e.g., using m5C or m6A) are necessary to mitigate these responses and ensure the safety profile.
· Characterization and Quality Control: The structural complexity and high molecular weight of circRNAs make them difficult to characterize. Standard mass spectrometry or sequencing methods require optimization to distinguish the true circular product from nicked or aggregated RNA impurities.

4. Conclusion and Recommendations
Circular RNAs represent a monumental evolutionary leap in the field of RNA therapeutics. By solving the stability and duration issues associated with linear mRNA, circRNAs unlock the potential for sustained, cost-effective, and highly potent therapies. From durable vaccines that may eliminate the need for boosters to in vivo CAR-T generation and long-term protein replacement, the clinical applications are vast.
It is recommended that biotechnology research centers and pharmaceutical industries invest in developing scalable, GMP-grade circularization and purification technologies. Furthermore, optimizing synthetic IRES elements and exploring targeted LNPs will be critical for clinical translation. The integration of bioinformatics and artificial intelligence to predict optimal circularization architectures and minimize off-target immune activation will accelerate the drug development pipeline. The future of genetic medicine lies not just in delivering RNA, but in delivering it with structural precision and durability.

References

1. Sanger, H. L., Gert Klotz, Dieter Riesner, Hans J. Gross, and Annemarie K. Kleinschmidt. (1976). Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proceedings of the National Academy of Sciences, 73(11), 3852-3856.
2. Jeck, William R., Jessica A. Sorrentino, Kai Wang, Michael K. Slevin, Christopher E. Burd, Jinze Liu, William F. Marzluff, and Norman E. Sharpless. (2013). Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA, 19(2), 141-157.
3. Wesselhoeft, R. Alexander, Piotr S. Kowalski, and Daniel G. Anderson. (2018). Engineering circular RNA for potent and stable translation in eukaryotic cells. Nature Communications, 9(1), 2629.
4. Chen, Chun-Yu, and Patrick Sarnow. (1995). Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science, 268(5209), 415-417.
5. Yang, Yisheng, Xin Fan, Mao Mao, Xiaomin Song, Ping Wu, Yang Zhang, and Zefeng Wang. (2017). Extensive translation of circular RNAs driven by N6-methyladenosine. Cell Research, 27(5), 626-641.
6. Wesselhoeft, R. Alexander, Piotr S. Kowalski, and Daniel G. Anderson. (2019). Engineering circular RNA for potent and stable translation in eukaryotic cells. Nature Communications, 10(1), 2629.
7. Qu, Liang, Zhipeng Yi, Yongkang Shen, Liang Lin, Feng Chen, Yanyan Xu, and Zonggui Chen. (2022). Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell, 185(10), 1728-1744.
8. Chen, Chun-Yu, and Patrick Sarnow. (2023). Circular RNA in medicine: Challenges and opportunities. Nature Reviews Drug Discovery, 22(5), 345-360